bioAffinity Technologies, a biotechnology company focusing on noninvasive diagnostics for early lung cancer detection, announced the appointment of Roberto Rios, CPA, and Dr. John J. Oppenheimer to its Board of Directors.
Mr. Rios brings extensive financial expertise, while Dr. Oppenheimer contributes vast clinical experience to bolster the company's growth plans.
The company also acknowledged Gary Rubin's resignation from the board.
Appointments to Board
Roberto Rios and Dr. John J. Oppenheimer join as new Board members, enhancing financial and clinical leadership.
Roberto Rios's Expertise
With over 40 years in executive finance leadership, Mr. Rios strengthens the company's financial foundation.
Dr. Oppenheimer's Clinical Insights
Dr. Oppenheimer, a clinical expert in asthma and COPD, will guide the company's clinical strategies.
Resignation of Gary Rubin
Gary Rubin steps down from the Board of Directors for personal reasons, acknowledging his past contributions.
- The new appointments bring combined expertise in finance and clinical research to propel the company's commercial growth and strategic direction.
- Mr. Rios's track record in corporate finance and governance and Dr. Oppenheimer's clinical leadership will play a crucial role in advancing the company's diagnostics and companion treatments.
The addition of Roberto Rios and Dr. John J. Oppenheimer to the Board of Directors marks a significant step for bioAffinity Technologies in strengthening its commercial growth and clinical strategies.